Domainex - About the company
Domainex is a series A company based in Cambridge (United Kingdom), founded in 2001. It operates as a Drug discovery CRO company for epigenetic research and inflammatory diseases. Domainex has raised $4.97M in funding, with a current valuation of £*****. The company has 775 active competitors, including 51 funded and 47 that have exited. Its top competitors include companies like Simulations Plus, Alloy Therapeutics and Manifold Bio.
Company Details
Domainex is a drug discovery CRO that develops small molecule compounds for epigenetic research and inflammatory diseases. Domainex's services include proprietary platforms based services such as Combinatorial Domain Hunting (for structural studies and assay development) and LeadBuilder (virtual and fragment-based approaches to hit identification), medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering. The company had won the £1.4m Biomedical Catalyst Award for the success of its Lead Compound in Pre-clinical Model of COPD. Domainex merged with NCE Discovery in 2007 to form a drug discovery company focussed on nucleotide triphosphate (NTP)-dependent proteins. The company's clientele includes UCB, FORMA Therapeutics, St George's University, The Institute of Cancer Research and Auspherix. Domainex claims that it has delivered on an average one candidate drug per year in the six years since 2010.
- Website
- www.domainex.co.uk/
- Social
- Registered Address
- DOMAINEX LIMITED CHESTERFORD RESEARCH PARK,LITTLE CHESTERFORD,SAFFRON WALDEN,ENGLAND,CB10 1XL
Key Metrics
Founded Year
2001
Location
Cambridge, United Kingdom
Stage
Series A
Total Funding
$4.97M in 6 rounds
Latest Funding Round
Post Money Valuation
£***** as on Nov 07, 2022
Investors
Ranked
12th among 775 active competitors
Annual Revenue
£11M as on Dec 31, 2024
Employee Count
93 as on Jan 31, 2022
Similar Companies
Legal entities associated with Domainex
Domainex is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Domainex Limited CIN: 4336899 , United Kingdom, Active | Dec 09, 2001 | $14.1M (As on Dec 31, 2024) | 117 (As on Dec 31, 2024) |
Sign up to download Domainex's company profile
Domainex's funding and investors
Domainex has raised a total funding of $4.97M over 6 rounds. Its first funding round was on 2007. Its latest funding round was a Grant (prize money) round on Apr 28, 2016 for $*****. 1 investor participated in its latest round. Domainex has 6 institutional investors.
Here is the list of recent funding rounds of Domainex:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 28, 2016 | 6465936 | Grant (prize money) | 1221557 | 5689816 | 3609234 | 4704090 |
Dec 2012 | 3051477 | Series A | 8815573 | 9562684 | 7425335 | |
Nov 01, 2011 | 8700335 | Grant (prize money) | 3228117 | 6386275 | 3929161 | 9685163 |
Access funding benchmarks and valuations. Sign up today!View details of Domainex's funding rounds and investors
Domainex's founders and board of directors
Founder? Claim ProfileDomainex's employee count trend
Domainex has 93 employees as of Jan 22. The total employee count is 22.0% more than what it was in Jan 21. Here is Domainex's employee count trend over the years:
Uncover Domainex's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Domainex's Competitors and alternates
Top competitors of Domainex include Simulations Plus, Alloy Therapeutics and Manifold Bio. Here is the list of Top 10 competitors of Domainex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Simulations Plus 1996, Lancaster (United States), Public | Developer of modeling and simulation software and consulting services provider | - | 65/100 | |
2nd |  Alloy Therapeutics 2017, Lexington (United States), Series D | Provider of drug discovery services | $117M | 63/100 | |
3rd |  Manifold Bio 2018, United States, Series A | Developer of tissue-targeted therapeutics using in vivo screening and AI design | $78.2M | 61/100 | |
4th |  Maiva Pharma 1996, Hosur (India), Late Stage | Manufacturer of sterile injectables | $125M | 61/100 | |
5th | Biotechnology research company developing biological drugs | $160M | 56/100 | ||
6th |  Biocom California 1995, San Diego (United States), Acquired | CRO focused on drug discovery & development for multiple therapeutic areas | - | - | 55/100 |
7th | Service to develop health products aiming to diagnose, prevent, delay the progression or treat hearing loss and tinnitus | $42.3M | 53/100 | ||
8th | Viva Biotech 2006, Shanghai (China), Public | Research services focused on drug discovery and development | - | 51/100 | |
9th |  Superluminal Medicines 2022, Boston (United States), Series A | Generative biological and chemical company focused on drug discovery | $158M | 50/100 | |
10th |  Syenex 2022, Chicago (United States), Series B | Developer of cell-specific delivery systems and programmable cell engineering payloads | $13.7M | 50/100 | |
12th | Domainex 2001, Cambridge (United Kingdom), Series A | Drug discovery CRO company for epigenetic research and inflammatory diseases | $4.97M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Domainex's competitors? Click here to see the top ones
Domainex's Investments and acquisitions
Domainex has made no investments or acquisitions yet.
News related to Domainex
Filter this list•
•
•
Domainex expands research operations with new facility at Unity CampusBusiness Weekly•Jul 11, 2023•Domainex, Howard Group
•
•
Amphista partners with Domainex to advance drug portfolioPharmaTimes•Oct 06, 2022•Amphista Therapeutics, Domainex
•
•
Domainex to expand research operations from new Cambridge facilityBusiness Weekly•Feb 10, 2022•Domainex
•
Parkinson’s UK and Domainex join forces to develop neuroinflammation therapiesPharmaTimes•Feb 03, 2022•Parkinsons, Domainex
•
FLIP sync: Collaboration for inhibitors and cancer treatmentsPharmaTimes•Jan 26, 2022•Ipsen, Domainex
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Domainex
Explore our recently published companies
- Juno Industries - Vancouver based, 2025 founded, Seed company
- Ryan Litfin - Eden Prairie based, 2008 founded, Seed company
- CIG Energy - Windermere based, 2025 founded, Funding Raised company
- National Commodity & Derivatives Exchange - Mumbai based, 2003 founded, Series B company
- Raj Petro Specialities - Chennai based, 1997 founded, Acquired company
- Valvoline - Lexington based, 1866 founded, Unfunded company
